Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer

Tumori

Volumn 85, Issue 6, 1999, Pages 494-497

  Mandalà, Mario ^a,b   Lissoni, Paolo ^a   Ardizzoia, Antonio ^a   Barni, Sandro ^a   Rovelli, Franco ^a   Confalonieri, Giorgio ^a   Malugani, Fabio ^a   Moro, Cecilia ^a   Fumagalli, Gabriele ^a   Giani, Luisa ^a   Tancini, Gabriele ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; L dopa; Metoclopramide; Prolactin

Indexed keywords

LEVODOPA; METOCLOPRAMIDE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; HYPERPROLACTINEMIA; METASTASIS; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE;

EID: 0033388407     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169908500613     Document Type: Article

References (12)

1. Barni S., Lissoni P., Tancini G., Crispino S., Paolorossi F., Rovelli F., Fumagalli G., Ferri L.: Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancer. Tumori, 72: 399-403, 1986.
2. Barrett A., Morgan L., Raggatt P.R., Hobbs J.R.: Bromocriptine in the treatment of advanced breast cancer. Clin. Oncol., 2: 373-377,1976.
3. Bhatavdekar J.M., Shan N.G., Balar D.B., Patel D.D., Bhaduri A., Trivedi S.N., Karelia N.H., Ghosh N., Shubla M.K., Giri D.D.: Plasma prolactin is an indicator of disease progression in advanced breast cancer. Cancer, 65: 2028-2032, 1990.
4. Bonneterre J., Peyrat J.P.: Prolactin receptor (PRL-R) and breast cancer. Eur. J. Clin. Oncol., 25: 1121-1222, 1999.
5. Clavenger C.V., Chang W.P., Ngo W., Pasha T.L., Montone K.T., Tomaszewski J.E.: Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracfine loop. Am. J. Pathol., 146: 695-705, 1995.
6. Holtkainp W., Nagel C.A., Wander H.E., Rauschecker H.F., Heyden D.: Hyperprolactinaemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int. J Cancer, 34: 323-328, 1984.
7. Jankovic B.D.: Neuroimmunomodulation. Ann. N. Y. Acad. Sci., 741: 1-38, 1994.
8. Johnson D.E., Ochieng J., Evans S.L.: The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. Anticancer Drugs, 6: 471-474, 1995.
9. Molitch M.E., Thomer M.O., Wilson C.: Management of prolactinomas. J. Clin. Endocrinol. Metab., 82: 996-1000, 1997.
10. Vinnitsky V.B.: Neurohumoral mechanisms of the formation of antitumoral activity. Ann. N. Y. Acad. Sci., 521: 195-199, 1988.
11. Ward H.C.W.: Combined anti-prolactin anti-oestrogen therapy for breast cancer. Clin. Oncol., 3: 91-95, 1977.
12. Welsch C.W., Nagasa H.: Prolactin and murine mammary tumorigenesis: a review. Cancer Res., 37: 951-963, 1977.